Particulars (Rs Crores) | Q3FY24 | Q3FY23 | YoY | Q2FY24 | QoQ |
---|---|---|---|---|---|
Revenue | 586.00 | 480.00 | 22.00% | 531.00 | 10.00% |
EBITDA | 133.00 | 77.00 | 74.00% | 114.00 | 17.00% |
EBITDA Margin (%) | 23.00% | 16.00% | 672 bps | 21.00% | 125 bps |
PAT | 83.00 | 63.00 | 31.00% | 84.00 | 0.00% |
Source: Company Filings; StockAxis Research
Q3FY24 Financial Performance
Marksans Pharma Limited delivered a healthy financial performance for the quarter
ended Q3FY24. Consolidated Revenue increased by 22% to Rs. 586 Crores as against
Rs 480 Crores for the same quarter of the previous year, driven by market share
gains, new launches, the addition of new customers, an increase in share with existing
customers, and incremental contributions from the acquired Teva facility. Consolidated
EBITDA surged by 74% on a YoY basis to Rs 133 Crores, whereas the EBITDA margin
expanded by 672 bps and stood at 23%, led by operating leverage benefits, cost optimization,
and reduction in raw material prices. Consolidated PAT increased by 31% on a YoY
basis to Rs 83 Crores, and the PAT margin stood at 14% followed by an expansion
of 99bps.
Revenue from operations in Q3FY24 is at Rs 586.1 Crores, out of which US revenues are at Rs 258 Crores, UK and Europe revenues at Rs 251 Crores, and Australia and New Zealand revenues at Rs 49 Crores.
US Market
US & North America Formulation business reported growth of 19% YoY to Rs. 258
Crores in Q3FY24 on account of new product launches and due to an increase in the
share of existing products.
UK and Europe Market
UK and Europe business registered a growth of Rs. 251 Crores from the UK and Europe
Formulation business in Q3FY24 as compared to Rs. 187 Crores, registering a growth
of 34.4% YoY.
Australia and New Zealand Market
Australia and New Zealand businesses reported Rs. 48.6 Crores in Q3FY24, which saw
a degrowth of 2.2% on a YoY basis.
RoW Market
RoW business reported Rs 29 Crores in Q3FY24, which grew by 22.2% on a YoY basis.
Key Conference Call Takeaways
Marksans Pharma recorded healthy earnings performance for the quarter ended Q3FY24. Considering robust R&D capabilities, healthy pipeline of product launches, Strong capabilities and experience to capture a significant part of the multibillion-dollar OTC opportunity, Backward integration, API manufacturing for captive consumption, and focus on inorganic growth, Marksans Pharma is well positioned to deliver steady earnings growth in the coming quarters.
At a CMP of Rs 160, the stock is trading at 16x its FY25e EPS, which appears reasonable and hence we maintain a HOLD rating on the stock.
Particulars (Rs Crores) | Q3FY24 | Q3FY23 | YoY | Q2FY24 | QoQ |
---|---|---|---|---|---|
Revenue | 586.00 | 480.00 | 22.00% | 531.00 | 10.00% |
COGS | 273.00 | 239.00 | 14.00% | 253.00 | 8.00% |
Gross Profit | 313.00 | 240.00 | 30.00% | 279.00 | 12.00% |
Gross Profit Margin (%) | 53.00% | 50.00% | 336 bps | 52.00% | 103 bps |
Employee Benefit Expense | 75.00 | 62.00 | 20.00% | 71.00 | 5.00% |
Other Expense | 106.00 | 102.00 | 4.00% | 93.00 | 13.00% |
EBITDA | 133.00 | 77.00 | 74.00% | 114.00 | 17.00% |
EBITDA Margin (%) | 23.00% | 16.00% | 672 bps | 21.00% | 125 bps |
Depreciation and Amortisation | 22.00 | 13.00 | 73.00% | 18.00 | 25.00% |
EBIT | 111.00 | 64.00 | 74.00% | 96.00 | 15.00% |
EBIT Margin (%) | 19.00% | 13.00% | 562 bps | 18.00% | 80 bps |
Finance Cost | 3.00 | 2.00 | 34.00% | 2.00 | 94.00% |
Other Income | 5.00 | 18.00 | -73.00% | 19.00 | -75.00% |
PBT | 113.00 | 79.00 | 42.00% | 114.00 | -1.00% |
Tax | 30.00 | 17.00 | 76.00% | 30.00 | -1.00% |
PAT | 83.00 | 63.00 | 31.00% | 84.00 | 0.00% |
PAT Margin (%) | 14.00% | 13.00% | 99 bps | 16.00% | -152 bps |
EPS (Rs) | 1.84 | 1.56 | 18.00% | 1.84 | 0.00% |
Source: Company Filings; StockAxis Research